GMAX Bio is Drug Discovery in China that focus on therapeutic antibody business. Founded in 2010. They cover business area such as developer, new drug, cardiovascular disease, metabolic disorder, cancer, G-protein couple receptor, GPCRs, therapeutic antibody, bibody, development, a robust pipeline, diabetes, obesity, nash, PAH, heart failure, well efficacy, low side effect, treatment.
2010
( 16 years old in 2026 )
Therapeutic Antibody
-
3F, Building 2, 288 Qiuyi Road
Binjiang District
Hangzhou, Zhejiang 310052
China
Private
developernew drugcardiovascular diseasemetabolic disordercancerG-protein couple receptorGPCRstherapeutic antibodybibodydevelopmenta robust pipelinediabetesobesitynashPAHheart failurewell efficacylow side effecttreatment
* We use standard office opening hours in near GMAX Bio's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
GMAX Bio is Drug Discovery business from China that founded in 2010 (16 years old in 2026), GMAX Bio business is focusing on Therapeutic Antibody.
GMAX Bio headquarter office and corporate office address is located in 3F, Building 2, 288 Qiuyi Road Binjiang District Hangzhou, Zhejiang 310052 China.
GMAX Bio was founded in China.
In 2026, GMAX Bio is currently focus on therapeutic antibody sector.
Above is snippet of Google Trends for "therapeutic antibody" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with GMAX Bio, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
